Study Drug Holds Promise As Alternative to Castration For Early Prostate Cancers

	Tweet

Traditionally, medical castration therapy following radiotherapy can significantly improve survival for men with locally advanced prostate cancer, compared to radiotherapy alone.

For those unwilling to undergo chemical castration however, results of an international study led by a Medical College of Wisconsin researcher show promise for an oral drug as an alternative. The study appears in the August issue of the Journal of Cancer Research and Clinical Oncology.

“In patients with locally-advanced disease, a daily 150 mg dose of bicalutamide, (Casodex ™) following initial radiotherapy, has shown significant clinical benefits in terms of overall survival and progression-free survival, compared with radiotherapy alone,” says study author William A See, M.D., chairman and professor of urology at the Medical College in Milwaukee, and chief of urologic surgery at Froedtert Hospital.

The double-blind, randomized study followed 1,370 early prostate cancer patients in the U.S., Sweden and Europe who received radiotherapy with curative intent. After a median follow-up of 7.2 years, the researchers found that those receiving a daily, 150 mg oral dose of Casodex ™ reduced their risk of disease progression by 44 percent, and their overall risk of death by 35 percent, compared to those receiving a placebo.

“Although many of the adverse effects of castration therapy are manageable, they can have a detrimental effect on quality of life,” says Dr. See “Here we have evaluated the efficacy and tolerability of a non-castration-based therapy, and found the survival rates to be similar.”

Medical College of Wisconsin

RELATED STORIES:
Artificial Light at Night: Higher Risk of Prostate Cancer   New gene test for prostate cancer at hand   Gleevec strangles drug-resistant, metastatic prostate cancer   New research could affect future treatment options for prostate cancer   Novel association between Parkinson’s disease and prostate cancer   Testosterone Replacement in Older Men Does Not Increase Risk of Prostate Cancer   Lower detection of prostate cancer with PSA screening in US than in a European randomized trial   Prostate Cancer Differential Diagnosis   Vaccine Approach Extends Life of Metastatic Prostate Cancer Patients   Untreated prostate cancer no death sentence   Prostate cancer therapy not tied to bladder cancer   Standard Treatment for Prostate Cancer May Encourage Spread of Disease   Counting tumor cells in blood predicts treatment benefit in prostate cancer   Pros and cons with “easier” prostate cancer surgery   Drug shows promise in prostate cancer spread to bone   Alternative therapy common in prostate cancer   Smoking Associated with Worse Outcomes in Patients with Prostate Cancer Treated by Radical Radiother   Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease   Radiation therapy technique reduces length of prostate cancer treatment   Statins don’t protect against cancer: study   Researchers find new biomarker for fatal prostate cancer   Soya products, beans and sunflower seeds reduce risk of contracting prostate cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]